Legend Biotech Corporation held its annual general meeting on June 12, 2025. Shareholders received the audited consolidated financial statements for the fiscal year ended December 31, 2024. The appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025, was ratified. Dr. Patrick Casey, Mr. Yau Wai Man Philip, and Dr. Fangliang Zhang were re-elected as Class II directors. Additionally, directors and officers were authorized to take necessary actions to effect the approved resolutions. All proposals were approved.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。